The media often report on the high cost of a variety of health-related behavior. As there is a limit to the resources available to public and private health plans, they are unable to make all new treatments available.
This raises question about the best way to decide which treatments should be offered under a health plan. Cost effectiveness analysis has emerge as a powerful tool to help determine priorities and guide these policy decisions. This note is meant as a background reading for a first class on cost effectiveness analysis or pharmacoeconomics.
PUBLICATION DATE: July 08, 2010 PRODUCT #: 910E07-PDF-ENG
This is just an excerpt. This case is about FINANCE & ACCOUNTING
Related Case Solutions & Analyses:
Cultivating Social Enterprise in Peru: Portfolio Approach
Global Fabricators Inc.
Corporate Solutions at Jones Lang LaSalle (2001)
Molycorp: Morgan Brothers’ Reverse Convertible Notes (C)
Cariboo Industrial Ltd.
Heartland Payment Systmems, Inc.
Hedging with Forwards and Futures
SIPEF: Biological Assets at Fair Value under IAS 41
Miracle Life, Inc.
The Business Case for Integrated Reporting: Insights from Leading Practitioners, Regulators, and Academics
